Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Depreciation & Amortization (CF) (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Depreciation & Amortization (CF) data on record, last reported at $14000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $14000.0; the TTM value through Dec 2025 reached $133000.0, down 59.2%, while the annual FY2025 figure was $133000.0, 55.67% down from the prior year.
  • Depreciation & Amortization (CF) reached $14000.0 in Q4 2025 per VRCA's latest filing, down from $23000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $200000.0 in Q2 2023 and bottomed at -$4000.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $87210.5, with a median of $100000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 790.91% in 2022, then tumbled 104.0% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $142000.0 in 2021, then dropped by 7.75% to $131000.0 in 2022, then fell by 22.9% to $101000.0 in 2023, then dropped by 0.99% to $100000.0 in 2024, then tumbled by 86.0% to $14000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $14000.0 in Q4 2025, $23000.0 in Q3 2025, and -$4000.0 in Q2 2025.